All In Biotech

Free tool

FAERS Monitor: Xelstrym

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215401 or its brand name (Xelstrym, Dextroamphetamine). Reports on generic versions are filed under their own applications.

Reports

3,815

Serious

1,880

49% of reports

Hospitalization

656

Death reported

119

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective386
  • fatigue305
  • nausea248
  • anxiety235
  • headache212
  • depression204
  • off label use186
  • insomnia149
  • pain149
  • condition aggravated143
  • dizziness143
  • somnolence143
  • feeling abnormal138
  • product dose omission issue131
  • vomiting119

Reports by year received

View as table
YearReports
200522
200612
20075
200818
200924
201039
201153
201287
201357
201459
2015219
2016576
2017160
2018190
2019172
2020158
2021176
2022331
2023359
2024455
2025353
2026290

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,344 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
depressionSignal2044.94.3645
anxietySignal2354.64.0657
somnolenceSignal1433.93.3311
feeling abnormalSignal1383.22.7206
insomniaSignal1493.12.6210
condition aggravatedSignal1432.62.2140
product dose omission issueSignal1312.52.1113
fatigueSignal3052.21.9196
headache2121.91.687
nausea2481.71.578
drug ineffective3861.61.596
dizziness1431.61.331
vomiting1191.41.213
pain1491.31.113
off label use1861.21.05

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.